Preview

Rational Pharmacotherapy in Cardiology

Advanced search

PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

https://doi.org/10.20996/1819-6446-2012-8-1-37-44

Full Text:

Abstract

According to recent guidelines, oral dabigatran etexilate is indicated for stroke and systemic embolism prevention in patients with atrial fibrillation (AF). Aim. Based on the RE-LY study to evaluate the cost-effectiveness of dabigatran etexilate versus warfarin prescribed in “real-world” settings from a Russian payer perspective. Material and methods. Markov model simulated AF patients at moderate to high risk of stroke while tracking clinical events and resulting functional disability. Acute event costs and resulting long-term follow-up costs incurred by disabled stroke survivors were calculated using general tariff agreement of Russian obligatory health insurance system and official national statistics. Clinical events, summarized as events per 100 patient-years, expected life years, total costs, and incremental cost effectiveness ratios (ICER) were calculated. Results. Over a lifetime, dabigatran etexilate treated patients experienced fewer intracranial haemorrhages and fewer ischaemic strokes. ICER of dabigatran etexilate was 461,602 roubles per one additional life year versus “real-world” warfarin. Conclusion. This study demonstrates that dabigatran etexilate is a cost-effective alternative to current care for the prevention of stroke and systemic embolism among Russian patients with AF .

About the Authors

Yu. B. Belousov
Russian National Research Medical University named after N.I. Pirogov
Russian Federation


V. Yu. Mareev
Moscow State University named after M.V. Lomonosov
Russian Federation


I. S. Yavelov
Russian National Research Medical University named after N.I. Pirogov
Russian Federation


D. Yu. Belousov
Center of pharmacoeconomic studies. http://healtheconomics.ru, Moscow, Russia
Russian Federation


References

1. Iguchi Y ., Kimura K., Shibazaki K., et al. Annual incidence of atrial fibrillation and related factors in adults. American Journal of Cardiology 2010; 106(8): 1129-33.

2. Jørgensen H.S., Nakayama H., Reith J., et al. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke 1996; 27(10): 1765-9.

3. McBride D., Brüggenjürgen B., McBride D. Anticoagulation treatment for the reduction of stroke in atrial fibrillation: a cohort study to examine the gap between guidelines and routine medical practice. Journal of thrombosis and thrombolysis 2007; 24: 65-72.

4. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139-51.

5. Industry Standard "Clinical and economic studies. General Provisions "91500.14.0001-2002. Available on: http://rspor .ru/mods/norm_doc/mz163_2002.pdf. Date of access: 02/22/2012. Russian (Отраслевой стандарт «Клинико-экономические исследования. Общие положения» 91500.14.0001- 2002. Доступно на: http://rspor .ru/mods/norm_doc/mz163_2002.pdf). Дата доступа: 22.02.2012.

6. Roskell N.S., Lip G.Y ., Noack H. et al. T reatments for stroke prevention in atrial fibrillation: a network metaanalysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010; 104: 1106–1115.

7. Epidemiology of stroke. Data Registers. Part one. Available at: http://medicalarea.ru/index.php?id=207. Date of access: 02/22/2012. Russian (Эпидемиология инсульта. Данные Регистров. Часть первая. Доступно на: http://medicalarea.ru/index.php?id=207. Дата доступа: 22.02.2012).

8. Hylek E.M., Go A.S., Chang Y . et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349:1019–1026.

9. Gilyarov M.Y . Thromboembolic complications in patients with atrial fibrillation: factors influencing the risk of their development and efficiency of antithrombotic therapy. Author’ abstract for the degree Doctor of Medical Science. Moscow, 2011. Russian (Гиляров М.Ю. Тромбоэмболические осложнения у больных с фибрилляцией предсердий: факторы, влияющие на риск их развития и эффективность антитромботической терапии. Автореферат диссертации на соискание учёной степени доктора медицинских наук. М., 2011).

10. Zuo H.J., Su J.L., Lin Y . et al. Analysis on long-term compliance of anticoagulation treatment and demands of disease management in patients with atrial fibrillation. Zhonghua Yi Xue Za Zhi 2010; 90 (32):2246-9.

11. Russian Statistical Yearbook 2011. Moscow: Rosstat, 2012. Available at: http://www.gks.ru/free_doc/doc_2011/year/year2011.rar . Date of access: 02/22/2012. Russian (Российский статистический ежегодник 2011. М.: Росстат; 2012. Доступно на: http://www.gks.ru/free_doc/doc_2011/year/year2011.rar . Дата доступа: 22.02.2012).

12. Mortality statistics: Metadata 2010. London: Office for National Statistics; 2011. Available at: http://www.ons.gov.uk/ons/guide-method/user-guidance/health-and-life-events/mortality-meta-data.pdf. Date of access: 02/22/2012.

13. Lloyd-Jones D., Adams R., Brown T., et al. Heart Disease and Stroke Statistics—2010 Update. A Re- port From the American Heart Association. Circulation 2010; 121: e46-e215.

14. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857–867.

15. Gusev E.I., Skvortsova V.I., Stakhovskaya L.V. The problem of stroke in the Russian Federation: the time of action. Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow) 2007;107(6): 4-10. Russian (Г усев Е.И., Скворцова В.И., Стаховская Л.В. Проблема инсульта в Российской федерации: время активных действий. Журнал неврологии и психиатрии им. С.С. Корсакова 2007;107(6): 4-10.

16. Belousov Yu.B., Yavelov I.S., Belousov D.Yu., Afanas'eva E.V. Analysis of the direct costs associated with the use of warfarin in patients with atrial fibrillation. Rational Pharmacotherapy in Cardiology 2011; 7(5): 561-566. Russian (Белоусов Ю.Б., Явелов И.С., Белоусов Д.Ю., Афанасьева Е.В. Анализ прямых затрат ассоциированных с применением варфарина у пациентов с фибрилляцией предсердий. РФК 2011; 7(5): 561-566).

17. Lee W., Christensen M., Joshi A., Pashos C. Long-Term Cost of Stroke Subtypes among Medicare Beneficiaries. Cerebrovasc Dis 2007;23:57–65.

18. General agreement on tariffs in 2011 the Territorial MHI programs for the city of St. Petersburg. Available at: http://www.spboms.ru/kiop/main?page_id=338. Date of access: 02/22/2012. Russian (Генеральное тарифное соглашение на 2011 год Т ерриториальной программы ОМС по г . Санкт-Петербург . Доступно на: http://www.spboms.ru/kiop/main?page_id=338. Дата доступа: 22.02.2012).

19. Belousov Yu.B., Belousov D.Yu., Beketov A.S. Clinical and economic analysis of the use of candesartan in elderly patients with hypertension for the prevention of nonfatal stroke. Consilium medicum 2009; 3: 22–27. Russian (Белоусов Ю.Б., Белоусов Д.Ю., Бекетов А.С. Клинико-экономический анализ применения кандесартана у пожилых пациентов с артериальной гипертонией для предотвращения развития нефатального инсульта мозга. Consilium medicum 2009; 3: 22–27).


For citation:


Belousov Y.B., Mareev V.Y., Yavelov I.S., Belousov D.Y. PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION. Rational Pharmacotherapy in Cardiology. 2012;8(1):37-44. (In Russ.) https://doi.org/10.20996/1819-6446-2012-8-1-37-44

Views: 555


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)